Skip to contents

A comprehensive dataset demonstrating advanced swimmer plot features including multiple milestones, patient demographics, and clinical characteristics. Designed to showcase the full capabilities of the swimmer plot function.

Usage

data(swimmer_unified_comprehensive)

Format

A data frame with 20 rows and 11 variables:

PatientID

Character. Unique patient identifiers (PT001-PT020)

StartTime

Numeric. Treatment start time (all patients start at 0)

EndTime

Numeric. Treatment end time in months (6-51 months)

BestResponse

Character. Best overall response (CR, PR, SD, PD)

Surgery

Numeric. Time of surgery in months (1-9 months, NA if no surgery)

FirstResponse

Numeric. Time of first response in months (3-18 months, NA if no response)

Progression

Numeric. Time of disease progression in months (4-36 months, NA if no progression)

DeathLastFU

Numeric. Time of death or last follow-up (6-18 months, NA if alive)

TreatmentType

Character. Type of treatment received

AgeGroup

Character. Patient age group (Young, Middle, Elderly)

ECOG

Numeric. ECOG performance status (0, 1, 2)

Source

Generated for ClinicoPath package demonstration

Examples

data(swimmer_unified_comprehensive)

# Comprehensive swimmer plot with milestones
swimmerplot(
  data = swimmer_unified_comprehensive,
  patientID = "PatientID",
  startTime = "StartTime",
  endTime = "EndTime", 
  responseVar = "BestResponse",
  milestone1Name = "Surgery",
  milestone1Date = "Surgery",
  milestone2Name = "First Response", 
  milestone2Date = "FirstResponse",
  milestone3Name = "Progression",
  milestone3Date = "Progression",
  milestone4Name = "Death/Last FU",
  milestone4Date = "DeathLastFU",
  personTimeAnalysis = TRUE,
  showInterpretation = TRUE
)
#> 
#>  SWIMMER PLOT
#> 
#> character(0)
#> 
#>  Timeline Summary Statistics         
#>  ─────────────────────────────────── 
#>    Metric                Value       
#>  ─────────────────────────────────── 
#>    Number of Patients     20.00000   
#>    Total Observations     20.00000   
#>    Median Duration        22.50000   
#>    Mean Duration          24.90000   
#>    Total Person-Time     498.00000   
#>    Mean Follow-up         24.90000   
#>    CR Rate (%)            30.00000   
#>    PD Rate (%)            25.00000   
#>    PR Rate (%)            25.00000   
#>    SD Rate (%)            20.00000   
#>  ─────────────────────────────────── 
#> 
#> 
#>  <div style='background-color: #e8f5e8; padding: 15px; border-radius:
#>  5px; margin: 10px 0;'>
#> 
#>  Clinical Interpretation
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Timeline
#>  Analysis:
#> 
#>  Study included 20 patients with 20 timeline observations. Median
#>  follow-up was 22.5 months (range: 6.0 to 51.0 months).
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Person-Time
#>  Analysis:
#> 
#>  Total person-time: 498.0 months. Average follow-up per patient: 24.9
#>  months.
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Response
#>  Pattern Analysis:
#> 
#>  Most common response was CR (30.0% of observations). Response
#>  distribution shows clinical patterns suitable for efficacy analysis.
#> 
#>  Person-Time Analysis                                                          
#>  ───────────────────────────────────────────────────────────────────────────── 
#>    Response Type    Patients    Total Time    Mean Time    Follow-up Density   
#>  ───────────────────────────────────────────────────────────────────────────── 
#>    CR                      6     207.00000    34.500000             2.899000   
#>    PD                      5      41.00000     8.200000            12.195000   
#>    PR                      5     145.00000    29.000000             3.448000   
#>    SD                      4     105.00000    26.250000             3.810000   
#>  ───────────────────────────────────────────────────────────────────────────── 
#> 
#> 
#>  Milestone Event Summary                                      
#>  ──────────────────────────────────────────────────────────── 
#>    Milestone         Events    Median Time    Time Range      
#>  ──────────────────────────────────────────────────────────── 
#>    Death/Last FU          7       9.000000    6 - 18 months   
#>    First Response        14       9.000000    3 - 18 months   
#>    Progression           14      12.000000    4 - 36 months   
#>    Surgery               17       3.000000    1 - 9 months    
#>  ──────────────────────────────────────────────────────────── 
#> 
#> 
#>  Advanced Clinical Metrics                                                                                                                                        
#>  ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>    Metric                           Value         95% CI         Unit                 Clinical Interpretation                                                     
#>  ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>    Median Follow-up Time             22.500000                   months               Central tendency of patient follow-up duration                              
#>    Interquartile Range               25.000000                   months               Middle 50% of follow-up duration range                                      
#>    Total Study Person-Time          498.000000                   months cumulative    Total observation time across all patients                                  
#>    Follow-up Density                  4.016000                   per 100 months       Number of patients per 100 units of observation time (descriptive metric)   
#>    Objective Response Rate (ORR)     55.000000    31.5 - 76.9    percent              Proportion with complete or partial response                                
#>    Disease Control Rate (DCR)        75.000000    50.9 - 91.3    percent              Proportion with response or stable disease                                  
#>  ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>